Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Acute intermittent porphyria].

A Catania, G Caimi

    Minerva Medica
    |November 10, 1983
    PubMed
    Summary
    This summary is machine-generated.

    Acute intermittent porphyria (AIP) is a rare genetic disorder causing intermittent attacks. It involves overproduction of hepatic ALA synthetase, leading to neurological symptoms due to blocked heme biosynthesis.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Impact of vancomycin resistance on attributable mortality among Enterococcus faecium bloodstream infections: propensity score analysis of a large, multicentre retrospective study.

    The Journal of antimicrobial chemotherapy·2025
    Same author

    Calculated whole blood viscosity in non-diabetic subjects with asymptomatic carotid atherosclerosis: How insulin resistance may affect blood viscosity.

    Clinical hemorheology and microcirculation·2024
    Same author

    Changes in RDW according to prognostic predictors in newly diagnosed multiple myeloma.

    Scientific reports·2024
    Same author

    Exploring perceptions of factors aiding the development of critical thinking in adult dysphagia: A study among fourth-year speech-language pathology students.

    The clinical teacher·2023
    Same author

    The unpredictable erythrocyte deformability alteration in some hematological disorders: How the classification of primary hyperviscosity syndromes could change.

    Clinical hemorheology and microcirculation·2023
    Same author

    An assessment of the hemorheological profile in patients with subclinical carotid atherosclerosis divided in relation to the number of cardiovascular risk factors and different degrees of insulin resistance.

    Clinical hemorheology and microcirculation·2021
    Same journal

    How to become a centenarian in four weeks?. Myths and limits of longevity recipes: a critical review.

    Minerva medica·2026
    Same journal

    Comparative efficacy and safety between intravenous recombinant human prourokinase and alteplase in acute ischemic stroke treatment: a meta-analysis of randomized controlled trials.

    Minerva medica·2026
    Same journal

    Efficacy and safety of oral tapentadol for cancer-related pain: an updated systematic review and meta-analysis.

    Minerva medica·2026
    Same journal

    Use of the neurostimulator in thyroidectomy procedures: comparison between vagal and recurrent laryngeal nerve stimulation.

    Minerva medica·2026
    Same journal

    Iron deficiency and risk of acute kidney injury after TAVI: a machine learning analysis.

    Minerva medica·2026
    Same journal

    Therapeutic adherence and health literacy: a perfect match in dyslipidemic patients.

    Minerva medica·2026
    See all related articles

    Area of Science:

    • Biochemistry
    • Genetics
    • Metabolic Disorders

    Context:

    • Acute intermittent porphyria (AIP) is a congenital disorder characterized by intermittent attacks.
    • Biochemical hallmarks include overproduction of hepatic ALA synthetase (ALA-s) and increased porphyrin precursors (PBG, ac S-ALA).
    • Clinical presentation involves abdominal neurological symptomatology.

    Purpose:

    • To identify the primary metabolic error in Acute Intermittent Porphyria.
    • To understand the biochemical and clinical characteristics of AIP.
    • To explore factors inducing ALA-s production and current treatment strategies.

    Summary:

    • AIP stems from a partial deficiency in an enzyme crucial for heme biosynthesis, leading to overproduction of ALA-s.
    • This metabolic block results in elevated porphyrin precursors and characteristic neurological symptoms.

    Related Experiment Videos

  • While treatment focuses on symptom management, ALA-s inhibitors represent a newer therapeutic approach.

    • Impact:

    • Provides a foundational understanding of AIP's pathophysiology.
    • Highlights the link between biochemical abnormalities and clinical manifestations.
    • Informs current and future therapeutic strategies for AIP management.